Claims
- 1. A substantially non-aqueous pharmaceutical gel composition for application on skin, said composition comprisingat least one vitamin D analogue selected from the group consisting of seocalcitol; calcipotriol; hydrate of calcipotriol; calcitriol; tacalcitol, maxacalcitol; paricalcitol; falecalcitriol; 1α, 24S-dihydroxy-vitamin D2; and 1(S),3(R)-dihydroxy-20(R)-[((3-(2-hydroxy-2-propyl)-phenyl)-methoxy)-methyl]-9,10-secopregna-5(Z),7(E),10(19)-triene and mixtures thereof, at least one corticosteroid, a viscosity-increasing excipient in an amount resulting in a viscosity in the range of from about 5 mPa.s to about 500 mPa.s, and at least one solvent selected from the group consisting of: (i) compounds of the general formula R3(OCH2C(R1)H)xOR2 (I) wherein x is in the range of 2-60, R1 in each of the x units independently is H or CH3, R2 is straight chain or branched C1-20alkyl or benzoyl, and R3 is H or phenylcarbonyloxy; (ii) di-(straight or branched)-C4-10 alkyl esters of C4-C8 dicarboxylic acids; (iii) straight or branched C12-18-alkyl benzoates; (iv) straight or branched C2-4-alkyl esters of straight or branched C10-18-alkanoic or -alkenoic acids; (v) propylenglycol diesters with C8-14-alkanoic acids; and (vi) branched primary C18-24 alkanols, said composition being stable when stored at 40° C. for 3 months.
- 2. The composition according to claim 1, which has a viscosity in the range of from about 10 mPa.s to about 250 mPa.s.
- 3. The composition according to claim 1, wherein the viscosity-increasing excipient is a thixotropic gelling agent.
- 4. The composition according to claim 3, wherein the thixotropic gelling agent is hydrogenated castor oil.
- 5. The composition according to claim 1, wherein said composition comprises a viscosity-increasing excipient which is a wax, polyethylene or a microcrystalline wax.
- 6. The composition according to claim 1, wherein said solvent is selected from compounds of the general formula H(OCH2C(R1)H)xOR2 (I) wherein R1, x, and R2 are as defined in claim 1 and mixtures thereof.
- 7. The composition according to claim 1, wherein R1 is CH3.
- 8. The composition according to claim 6, wherein said solvent is polyoxypropylene-15-stearyl ether.
- 9. The composition according to claim 1, wherein said vitamin D analogue is selected from the group consisting of calcipotriol; calcitriol; tacalcitol, maxacalcitol; 1(S),3(R)-dihydroxy-20(R)-[((3-(2-hydroxy-2-propyl)-phenyl)-methoxy)-methyl]-9,10-seco-pregna-5(Z),7(E),10(19)-triene, as well as mixtures thereof,
- 10. The composition according to claim 1, wherein the vitamin D analogue is effective against psoriasis and sebo-psoriasis of the scalp in humans.
- 11. The composition according to claim 1, wherein said vitamin D analogue is calcipotriol or its hydrate.
- 12. The composition according to claim 1, wherein said corticosteroid is selected from the group consisting of Betamethasone, Clobetasol, Clobetasone, Desoximethasone, Diflucortolon, Diflorasone, Fluocinonid, Flumethasone, Fluocinolon, Fluticasone, Fluprednidene, Halcinonide, Hydrocortisone, Momethasone, Triamcinolon, Pharmaceutically acceptable esters thereof, acetonides thereof and mixtures thereof.
- 13. The composition according to claim 12, wherein said esters or acetonides are selected from the group consisting of 17-valerate, 17-propionate, 17,21-dipropionate acetonide, acetonide-21N-benzoyl-2-methyl-β-alaninate, acetonide-21-(3,3-dimethylbutyrate) and 17-butyrate.
- 14. The composition according to claim 1, wherein said composition contains 0.001-0.25 mg/g or ml of said vitamin D analogue and 0.05-2 mg/g or ml of said corticosteroid.
- 15. The composition according to claim 1, wherein said composition comprises the following ingredients (per g of the composition):betamethasone (as dipropionate: 0.643 mg) 0.5 mg calcipotriol (as hydrate: 52.2 μg) 50 μg polyoxypropylene-15-stearyl ether 170 mg hydrogenated castor oil 30 mg heptamethylnonane to make 1 g.
- 16. The composition according to claim 1, which further comprises an antifungal agent.
- 17. The composition according to claim 1 for application on the scalp.
- 18. The composition according to claim 17, additionally comprising a surfactant.
- 19. The composition according to claim 18, wherein the surfactant is selected from the group consisting of octoxynol-n of formula C8H17C6H4(OCH2CH2)nOH, wherein n is an integer of from 1 to 70, nonoxynol-n of formula C9H19C6H4(OCH2CH2)pOH, wherein p is an integer of from 4 to 40, and a polyoxyethylene C12-22 alkyl ether.
- 20. A method of treating psoriasis or sebo-psoriasis of the scalp, the method comprising administering to an affected skin area of a patient in need thereof an effective amount of the composition according to claim 1.
- 21. The method of claim 20, wherein said composition is administered once or twice a day.
- 22. The method of claim 20, wherein said composition is administered to the scalp.
- 23. The method of claim 20, wherein said composition is administered once a day.
Parent Case Info
This application claims the benefit of Provisional Application No. 60/243,471 filed Oct. 27, 2000.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
4569935 |
Rosenberg et al. |
Feb 1986 |
A |
4610978 |
Dikstein et al. |
Sep 1986 |
A |
5185150 |
DeLuca et al. |
Feb 1993 |
A |
5827520 |
de Salvert |
Oct 1998 |
A |
Foreign Referenced Citations (3)
Number |
Date |
Country |
0 471 872 |
Feb 1992 |
EP |
WO9414453 |
Jul 1994 |
WO |
WO0064450 |
Nov 2000 |
WO |
Non-Patent Literature Citations (2)
Entry |
Ruzick et al., British Journal of Dermatology 1998; 139: 254-258.* |
Gennaro, Remington's Pharmaceutical Sciences, 18th ed., p. 1310-1311. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/243471 |
Oct 2000 |
US |